Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval
This study aims to determine whether cancer drugs granted accelerated approval from the US Food and Drug Administration ultimately demonstrate clinical benefit and to evaluate the basis of conversion to regular approval.